Shares of Nuformix plc (LON:NFX – Get Free Report) were down 10% during mid-day trading on Monday . The stock traded as low as GBX 0.05 ($0.00) and last traded at GBX 0.05 ($0.00). Approximately 1,986,748 shares were traded during trading, a decline of 82% from the average daily volume of 10,762,529 shares. The stock had previously closed at GBX 0.05 ($0.00).
Nuformix Price Performance
The company has a 50 day moving average of GBX 0.05 and a 200 day moving average of GBX 0.12. The company has a quick ratio of 3.35, a current ratio of 1.12 and a debt-to-equity ratio of 1.17. The stock has a market capitalization of £368,689.50, a price-to-earnings ratio of -1.63 and a beta of 1.22.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
See Also
- Five stocks we like better than Nuformix
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Power Up: Gaming Industry Expansion Fuels Stock Opportunities
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- These 3 Quirky ETFs May Be Strong Plays in 2025
- The Significance of Brokerage Rankings in Stock Selection
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.